Latest & greatest articles for aripiprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aripiprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aripiprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for aripiprazole

41. Aripiprazole (Abilify®) tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripi

Aripiprazole (Abilify®) tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripi Aripiprazole (Abilify®) tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes (...) responded to aripiprazole treatment Aripiprazole (Abilify®) tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made

Health Technology Assessment (HTA) Database.2009

42. Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms

Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms Article Text Therapeutics Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms Statistics from Altmetric.com No Altmetric data available

Evidence-Based Mental Health2009

43. Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder

Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder Article Text Therapeutics Switching to aripiprazole from olanzapine leads to weight loss in overweight people

Evidence-Based Mental Health2009

44. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia 18765484 2008 11 04 2008 11 18 2015 11 19 1535-7228 165 11 2008 Nov The American journal of psychiatry Am J Psychiatry A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. 1432-41 10.1176/appi.ajp.2008.07061035 Aripiprazole is a dopamine partial agonist approved for use (...) in adults for short- and long-term treatment of schizophrenia and bipolar disorder. This study was designed to examine the acute efficacy, safety, and tolerability of aripiprazole for adolescents with schizophrenia. This was a 6-week multicenter, double-blind, randomized, placebo-controlled trial. Subjects 13 to 17 years old with a DSM-IV diagnosis of schizophrenia and a Positive and Negative Syndrome Scale (PANSS) total score of 70 or more were randomly assigned (1:1:1 ratio) to placebo or 10 or 30 mg

EvidenceUpdates2008

46. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering

A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering 18794650 2008 09 16 2008 11 24 2015 11 19 1533-712X 28 5 2008 Oct Journal of clinical psychopharmacology J Clin Psychopharmacol A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering (...) of previous antipsychotics versus add-on and simultaneous tapering. 540-3 10.1097/JCP.0b013e3181842586 Although recent treatment guidelines for schizophrenia recommend that the prior antipsychotic agent should remain stable for at least 2 weeks when aripiprazole is introduced, there is no trial-based evidence to support this strategy. This study was designed to compare this strategy with another conventional one in patients with schizophrenia. We conducted a randomized, 14-week, open-label trial

EvidenceUpdates2008

48. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia

Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia Article Text Therapeutics Haloperidol, olanzapine and risperidone reduce

Evidence-Based Mental Health2008

49. Aripiprazole versus typical antipsychotic drugs for schizophrenia.

Aripiprazole versus typical antipsychotic drugs for schizophrenia. BACKGROUND: Aripiprazole is a relatively new antipsychotic drug, said to be the prototype of a new third generation of antipsychotics; the so-called dopamine-serotonin system stabilisers. In this review we examine how the efficacy and tolerability of aripiprazole differs from that of typical antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other typical antipsychotics for people (...) with schizophrenia and schizophrenia-like psychoses. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group Trials Register (November 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected references of all identified studies for further trials. We contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised trials comparing aripiprazole

Cochrane2008

50. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study 18344725 2008 03 17 2008 05 27 2015 11 19 0271-0749 28 2 2008 Apr Journal of clinical psychopharmacology J Clin Psychopharmacol The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. 156-65 10.1097/JCP.0b013e31816774f9 (...) Nonresponse to one or more antidepressants is common and an important public health problem. This study evaluated the efficacy and safety of adjunctive aripiprazole or placebo to standard antidepressant therapy (ADT) in patients with major depressive disorder who showed an inadequate response to at least 1 and up to 3 historical and 1 additional prospective ADT. The study comprised a 7-28-day screening, an 8-week prospective treatment, and a 6-week randomization phase. During prospective treatment

EvidenceUpdates2008

51. Review: aripiprazole for schizophrenia—more high quality research required

Review: aripiprazole for schizophrenia—more high quality research required Review: aripiprazole for schizophrenia—more high quality research required | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: aripiprazole for schizophrenia—more high quality research required Article Text Therapeutics Review: aripiprazole for schizophrenia—more high quality research required Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article please use the link below which

Evidence-Based Mental Health2008

52. Continuing aripiprazole after stabilisation of a manic or mixed episode of bipolar I disorder delays relapse

Continuing aripiprazole after stabilisation of a manic or mixed episode of bipolar I disorder delays relapse Continuing aripiprazole after stabilisation of a manic or mixed episode of bipolar I disorder delays relapse | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Continuing aripiprazole after stabilisation of a manic or mixed episode of bipolar I disorder delays relapse Article Text Therapeutics Continuing aripiprazole after stabilisation of a manic or mixed episode of bipolar I disorder delays relapse Statistics from Altmetric.com

Evidence-Based Mental Health2008

53. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes (...) in patients with schizophrenia Colombo GL, Caruggi M, Di Matteo S, Rossi A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the cost-effectiveness of aripiprazole versus olanzapine for the treatment of patients

NHS Economic Evaluation Database.2008

54. Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alone

Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alone Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alone | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alone Article Text Therapeutics Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alone Statistics from Altmetric.com

Evidence-Based Mental Health2008

55. Adjunctive aripiprazole improves symptoms in antidepressant refractory major depressive disorder

Adjunctive aripiprazole improves symptoms in antidepressant refractory major depressive disorder Adjunctive aripiprazole improves symptoms in antidepressant refractory major depressive disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adjunctive aripiprazole improves symptoms in antidepressant refractory major depressive disorder Article Text Therapeutics Adjunctive aripiprazole improves symptoms in antidepressant refractory major depressive disorder Statistics from Altmetric.com No Altmetric data available for this article. QUESTION

Evidence-Based Mental Health2008

56. Aripiprazole reduces acute mania compared with haloperidol in bipolar I disorder and causes fewer adverse effects

Aripiprazole reduces acute mania compared with haloperidol in bipolar I disorder and causes fewer adverse effects Aripiprazole reduces acute mania compared with haloperidol in bipolar I disorder and causes fewer adverse effects | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aripiprazole reduces acute mania compared with haloperidol in bipolar I disorder and causes fewer adverse effects Article Text Therapeutics Aripiprazole reduces acute mania compared with haloperidol in bipolar I disorder and causes fewer adverse effects Statistics from

Evidence-Based Mental Health2007

57. Abilify (aripiprazole)

Abilify (aripiprazole) 1/29 ?EMEA 2005 SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Abilify. For information on changes after approval please refer to module 8. 1. Introduction Schizophrenia is a major psychotic disorder. Its essential features consist of a mixture of characteristic signs and symptoms that have been present for a significant length of time during a 1-month period (or for a shorter time if successfully treated), with some signs (...) because their safety profile is complex. The in vitro affinity profile of aripiprazole for dopamine and serotonin receptors is similar to the one of so-called atypical antipsychotics. It is postulated that aripiprazole's mechanism of action is novel as it involves a combination of partial agonist action (agonist/antagonism) at dopamine D2 and serotonin 5-HT 1A receptors and antagonism at serotonin 5-HT 2A receptors. 2. Chemical, pharmaceutical and biological aspects Composition Abilify contains

European Medicines Agency - EPARs2006

58. Abilify Discmelt (Aripiprazole) Orally Disintegrating Tablets

Abilify Discmelt (Aripiprazole) Orally Disintegrating Tablets Drug Approval Package: Abilify Discmelt (Aripiprazole) NDA #021729 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Abilify Discmelt (Aripiprazole) Orally Disintegrating Tablets Company: Otsuka Pharmaceutical Co., Ltd. Application No.: 021729 Approval Date: 06/07/2006 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: August 22, 2007 Note: Documents in PDF format require

FDA - Drug Approval Package2006

59. Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia

Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia Article Text Therapeutics Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia Free Professor Ann M Mortimer , BSc MB ChB MMedSc FRCPsych Statistics from Altmetric.com No Altmetric data

Evidence-Based Mental Health2005

60. Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder

Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder Article Text Therapeutics Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder Free James P Kelleher , MD Statistics from Altmetric.com No Altmetric data available for this article. Potkin SG

Evidence-Based Mental Health2005